Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BeOne Medicines makes and sells cancer drugs that target specific genetic weaknesses in tumors.
BeOne Medicines is a cancer drug company. It discovers and sells medicines that attack tumors by targeting specific gene mistakes inside cancer cells, rather than blasting all fast-dividing cells the way old-school chemotherapy does. Its biggest seller is Brukinsa, a pill for blood cancers like chronic lymphocytic leukemia, which brings in the large majority of revenue — roughly two-thirds of total sales. The company mainly earns money by selling these pills to hospitals, clinics, and pharmacies, with insurers and government health programs footing most of the bill. Its main market is the United States, followed by Europe and China.
Think of it as a locksmith for cancer: instead of knocking down the whole door with chemo, it studies the lock on a tumor's surface and makes a key that only fits that one broken lock. That precision is why its drugs often work better and with fewer brutal side effects. BeOne got to this point through a big transformation — it used to be called BeiGene and was known for selling cheaper cancer drugs in China. In 2025 it renamed itself BeOne Medicines, moved its legal home to Switzerland, and now leans heavily on Brukinsa's rapid growth in the US and Europe. Newer medicines, especially a blood cancer drug called sonrotoclax and a solid-tumor treatment called tislelizumab, are being pushed forward to reduce reliance on that one big seller.
The company spends heavily on research — often more than it earns in profit — because cancer drug development is expensive and most experiments fail. Lately it has been cutting costs and getting closer to steady profitability as Brukinsa sales scale up. It has no dividend and does not buy back meaningful amounts of stock; instead, any spare cash goes back into clinical trials and launching new drugs. The big risks are familiar for any drugmaker: patent fights, pricing pressure from insurers, and the constant need to find the next blockbuster before the current one loses its patent protection.
Saved answer · last researched 11 Oct 2026